

Current PWS Research

Kathleen Jones, CEO & Founder Dr Diane Webster, Research Director





PRADER-WILLI RESEARCH FOUNDATION AUSTRALIA

Diane's video here

Slide formatting to match slide 2

Dr Diane Webster, Research Director

Prader Willi Research Foundation Australia

Our vision is to improve clinical outcomes and deliver better treatments for people living with PWS











PRADER-WILLI RESEARCH FOUNDATION AUSTRALIA

Prader Willi Research Foundation Australia

Strategic research focus:

- gene activation by epigenetic editing
 - therapies targeting the underlying cause of PWS
- new therapies for the most important symptoms
 - Basic science to clinical trials
- Infrastructure
 - to support all stages of therapy development
- delivering better healthcare



Kath – video of you will go in this box PRADER-WILL





PWS research themes

Capturing PWS lived experience

- patient voice
- caregiver burden
- therapy choices (risk tolerance)
- consensus definitions

Original Research Article

Measuring Meaningful Benefit-Risk Tradeoffs to Promote Patient-Focused Drug Development in Prader-Willi Syndrome: A Discrete-Choice Experiment

Jui-Hua Tsai*, Norah L. Crossnohere*, Theresa Strong, and John F. P. Bridges

REVIEW

Behavioral features in Prader-Willi syndrome (PWS): consensus paper from the International PWS Clinical Trial Consortium

Lauren Schwartz^{1,2*}, Assumpta Caixàs^{3,4}, Anastasia Dimitropoulos⁵, Elisabeth Dykens⁶, Jessica Duis⁷, Stewart Einfeld⁸, Louise Gallagher⁹, Anthony Holland¹⁰, Lauren Rice¹¹, Elizabeth Roof¹², Parisa Salehi¹³, Theresa Strong^{1,14}, Bonnie Taylor¹⁵ and Kate Woodcock¹⁶




MDM Policy & Practice 1–9 © The Author(s) 2021 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/23814683211039457 journals-sagepub.com/home/mdm **©SAGE**



Open Access



Research theme: behind the scenes





RESEARCH ARTICLE




PRADER-WILLI RESEARCH FOUNDATION AUSTRALIA


Smchd1 is a maternal effect gene required for genomic imprinting


Iromi Wanigasuriya^{1,2†}, Quentin Gouil^{1,2†}, Sarah A Kinkel^{1,2}, Andrés Tapia del Fierro^{1,2}, Tamara Beck¹, Ellise A Roper³, Kelsey Breslin¹, Jessica Stringer⁴, Karla Hutt⁴, Heather J Lee³, Andrew Keniry^{1,2}, Matthew E Ritchie^{1,2,5}, Marnie E Blewitt^{1,2*}

¹Walter and Eliza Hall Institute of Medical Research, Parkville, Australia; ²The Department of Medical Biology, The University of Melbourne, Parkville, Australia; ³Faculty of Health and Medicine, The University of Newcastle, Newcastle, Australia; ⁴Monash Biomedicine Discovery institute, Monash University, Clayton, Australia; ⁵The Department of Mathematics and Statistics, The University of Melbourne, Parkville, Australia

Abstract Genomic imprinting establishes parental allele-biased expression of a suite of mammalian genes based on parent-of-origin specific epigenetic marks. These marks are under the control of maternal effect proteins supplied in the oocyte. Here we report epigenetic repressor *Smchd1* as a novel maternal effect gene that regulates the imprinted expression of ten genes in mice. We also found zygotic SMCHD1 had a dose-dependent effect on the imprinted expression of seven genes. Together, zygotic and maternal SMCHD1 regulate three classic imprinted clusters and eight other genes, including non-canonical imprinted genes. Interestingly, the loss of maternal







brighter together

Validation


>2500 hits

- Replicate the findings in the same assay
- Test to ensure they don't inhibit the assay
- Replicate in a different assay

Lead molecule selection (5-6 compounds)



Behind the Scenes – digging deeper



Clinical studies



PRADER-WILLI RESEARCH FOUNDATION AUSTRALIA


Clinical Trials


- Intranasal Carbetocin (LV-101/Levo Therapeutics)
- DCCR (Soleno Therapeutics)
- Microbiome
- Growth hormone
- Many other studies are underway

Clinical Observations and Biomarkers

- tools for understanding what's happening at a clinical level
- new therapeutic targets, opportunities, learnings

Sleep, exercise, COVID, meta-analysis... and more...






Supporting research

PRADER-WILLI RESEARCH FOUNDATION

AUSTRALIA

Nothing about me – without me! Advocacy has a role at every stage. Share your stories





Chromosome 15 Biobank

The Biobank will collect and store

- Biological samples
- Clinical histories and detailed-phenotypic data

The objective of the biobank is to enhance PWS and AS research and clinical practice by:

- Making data and biological specimens available to other researchers and industry, to answer key questions
- Fostering collaboration between academics and industry
- Maximising the impact of laboratory and clinical assessments and data linkage for people with PWS and their families
- Efficiency is the Moto: 'collect once and share rather than 100 times and don't'

For more information please contact emma.baker@mcri.edu.au







Laurence G & Jean E Brown Charitable Trust

Prader Willi Research Foundation Australia

"This artwork was created by children with PWS who look forward to the day better treatments exist"





We'd love to hear from you

- info@praderwilli.org.au
- diane.webster@praderwilli.org.au